At the Extraordinary General Meeting of
Resolution on amendment of the limits for the number of members of the Board of Directors in the Articles of Association
The general meeting resolved, in accordance with the Board of Directors' proposal, to amend the limits for the number of members of the Board of Directors, from a minimum of four (4) members to a minimum of three (3) members.
Determination of the number of members of the Board of Directors
The general meeting resolved, in accordance with the Nomination Committee's proposal, that the number of members of the Board of Directors elected by the general meeting for the period until the end of the next Annual General Meeting shall be three (3) members without deputies.
Determination of fees to the members of the Board of Directors
The general meeting resolved, in accordance with the Nomination Committee's proposal, that the fees shall remain unchanged in relation to the resolution at the Annual General Meeting on
Election of members of the Board of Directors
The general meeting resolved, in accordance with the Nomination Committee's proposal, to re-elect the Board members
Resolution on amendment of the limits for the share capital and the number of shares in the Articles of Association and approval of the Board of Directors' resolution to issue new shares and warrants with preferential rights for existing shareholders
The general meeting resolved, in accordance with the Board of Directors' proposal, to approve the Board of Directors' resolution on
The right to subscribe for units shall, with preferential rights for existing shareholders, be granted to those who are registered as shareholders in the company on the record date for the issue on
Each (1) warrant of series TO2 entitles the holder to subscription of one (1) new share in the company during the period from and including
The complete terms and conditions for warrants of series TO2 are available on the company's website, www.nextcellpharma.com. According to the terms and conditions of the warrants, the subscription price and the number of shares that each warrant entitles to subscription of may be subject to recalculation in certain cases.
In order to enable the rights issue, the general meeting resolved to amend the limits for the share capital and the number of shares in the Articles of Association.
For more information about
Tel: +46 8 735 5595
E-mail: info@nextcellpharma.com
Certified Adviser
About
NextCell is a cell therapy company that is in phase 2 studies with the drug candidate
https://news.cision.com/nextcell-pharma-ab/r/bulletin-from-the-extraordinary-general-meeting-of-nextcell-pharma-ab--publ-,c3988366
https://mb.cision.com/Main/15834/3988366/2822654.pdf
(c) 2024 Cision. All rights reserved., source